PK Basics

Understanding Drug Half-Life: A Complete Guide

Pharazi.ai TeamMarch 15, 20267 min read

What Is Drug Half-Life?

The elimination half-life (

) is the time required for the plasma concentration of a drug to decrease by exactly 50%.

It directly determines:

  • How often a drug must be dosed to maintain therapeutic levels
  • How long it takes to reach steady state after initiating therapy
  • How long it takes to wash out after discontinuation

Mathematical Definition

Half-life is derived from the first-order elimination rate constant (

):

Since

, we can also write:

Clinical Significance of Half-Life

1

Dosing Interval Selection

For most agents, the dosing interval (

) approximates one half-life, keeping peak-to-trough fluctuations within a 2-fold range.

Drug Typical
Typical Dosing Interval
Amoxicillin 1 h q8h
Metformin 6.2 h BID
Amlodipine 35 h Once daily
Amiodarone 40–55 days Once daily (requires loading)
2

Time to Steady State

It takes approximately 4–5 half-lives to reach steady-state concentrations, regardless of dose.

Half-Lives Elapsed % Steady State
1 50%
2 75%
3 87.5%
4 93.75%
5 ~97%
3

Washout Period

After stopping a drug, it takes 4–5 half-lives to eliminate ~97% of systemic exposure. This is critical for:

  • Clinical trial crossover designs — preventing carryover effects
  • Switching therapies — avoiding antagonistic overlap
  • Pre-surgical drug holidays — minimizing bleeding risks

Worked PK Calculation Example

Clinical Scenario: Drug X has

and
.

1

Calculate Half-Life

2

Estimate Time to Steady State

The physician should expect stable trough concentrations by Day 3.

Context-Dependent Variations

  • Hepatic/Renal Impairment — Reduces
    , increasing
  • Obesity — May increase
    for lipophilic drugs
  • Age — Pediatric and geriatric populations show altered
    and
  • Drug-Drug Interactions — CYP450 inhibitors slash
    , driving up

Try It Yourself on Pharazi.ai

Use the Half-Life Calculator to instantly compute

from concentration-time pairs or clearance/volume data.

References

  1. Rowland M, Tozer TN. Clinical Pharmacokinetics and Pharmacodynamics. 4th ed.
  2. Shargel L, Yu ABC. Applied Biopharmaceutics & Pharmacokinetics. 7th ed.
  3. Bauer LA. Applied Clinical Pharmacokinetics. 3rd ed.
half-lifepharmacokineticseliminationdosing intervalsteady stateclearancevolume of distribution

Related Articles